• Jeffrey E Nowak, Kelli Harmon, Charles C Caldwell, and Hector R Wong.
• Department of Pediatrics, Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
• Pediatr Crit Care Me. 2012 Sep 1; 13 (5): e323e329e323-9.

ObjectiveWe previously demonstrated that altered zinc homeostasis is an important feature of pediatric sepsis, thus raising the possibility of zinc supplementation as a therapeutic strategy in sepsis. Herein, we tested the hypothesis that prophylactic zinc supplementation would be beneficial in a murine model of peritoneal sepsis.DesignMurine model of sepsis (intraperitoneal fecal-slurry injection).SettingBasic science research laboratory.SubjectsC57BL/6 male mice.InterventionsIntraperitoneal fecal-slurry injection, with or without zinc supplementation (10 mg/kg of intraperitoneal zinc gluconate for 3 days prior to intraperitoneal fecal-slurry injection).Measurements And Main ResultsSurvival over 3 days following intraperitoneal fecal-slurry injection, markers of inflammation, bacterial load studies, and immunophenotyping studies. Zinc-supplemented mice demonstrated a significant survival advantage compared to control (nonsupplemented) mice. Zinc-supplemented mice also demonstrated moderate reductions of inflammation and immune activation. The survival advantage primarily correlated with reduced in vivo bacterial load in zinc-supplemented mice, compared to controls. In addition, peritoneal macrophages harvested from zinc-supplemented mice demonstrated a significantly enhanced phagocytosis capacity for Escherichia coli and Staphylococcus aureus, compared to peritoneal macrophages harvested from control mice.ConclusionProphylactic zinc supplementation reduces bacterial load and is beneficial in a murine model of peritoneal sepsis.

27 keywords...

hide…